Inflammatory Factors in Major and Macular Branch Retinal Vein Occlusion

Noma, Hidetaka; Funatsu, Hideharu; Mimura, Tatsuya; Eguchi, Shuichiro; Shimada, Katsunori

doi:10.1159/000335047

Cited by 27 publications

(24 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The novel DDS applicator is a well-established applicator system to apply sustained release of DEX-implants into the vitreous cavity. With favorable confidence in intravitreal DEX injections (17,18,19) among treating physicians, the sharper novel DDS needle will increase in use as confirmed by our measurements in this experimental study.…”

Section: Dds Applicatorsupporting

confidence: 64%

Penetration Force, Geometry, and Cutting Profile of the Novel and Old Ozurdex Needle: The MONO Study

Meyer

Liu

Brinkmann

et al. 2014

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

On behalf of the German Retinal Vein Occlusion GroupAbstract Purpose: To investigate the geometry, penetration force, and cutting profile of the novel and old needle of the drug delivery system (DDS) for Ozurdex injections in a standardized laboratory setting. Methods: In this experimental study, the normative geometrical data of the DDS needle were systematically analyzed according to nomenclature DIN 13097 (ISO 7864) and ISO 9626. The force to penetrate a standardized 0.4-mm-thick polyurethane foil was measured by a penetrometer, when the needle was piercing, cutting, and sliding through the foil and plotted as a load-displacement diagram. Magnified images of the consecutive cut were taken after the entire penetration through the foil. Results: In this experimental study, the mean point length was equal to 3.34 mm (3.28-3.36 mm) for the old DDS needle versus 3.33 mm (3.30-3.36 mm) for the new DDS needle. The secondary bevel length was 1.64 mm (1.42-1.73 mm) for the new and 1.66 mm (1.62-1.69 mm) for the old needle. The primary angle was 9.2°(9.0°-9.5°) for the old and 8.9°(8.5°-9.0°) for the new needle, respectively. The secondary bevel angle was 117.2°( 116°-118°) for the old and 111.4°(110°-113°) for the new needle. The mean penetration force of the old DDS needles was significantly higher at all phases of the penetration experiment: The mean piercing force was 0.7 Newton (N) with the old and 0.47 N with the new DDS needle. The mean cutting force was remarkable higher with 1.1 N for the old DDS needle versus 0.78 N for the new DDS needle. The dilatation phase was not statistically significant between 0.94 and 0.99 N in both DDS needles. The friction phase was maintained at significantly higher levels with the old DDS needle of 0.47 N, whereas it returned to the lowest measurements of 0.11 N with the new DDS needle. Both DDS systems induced a characteristic chevron-shaped incision. Conclusion: A comparison of the old and new DDS needles demonstrated a reduced penetration force with the modified new DDS needle, which may help to achieve a smooth penetration through the human sclera.

show abstract

Section: Dds Applicatorsupporting

confidence: 64%

Penetration Force, Geometry, and Cutting Profile of the Novel and Old Ozurdex Needle: The MONO Study

Meyer

Liu

Brinkmann

et al. 2014

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…We recently reported that intraocular levels of several inflammatory factors were significantly correlated with the severity of ME in BRVO,3 4 suggesting an important role of inflammation in the mechanism of ME. This hypothesis is supported by the Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) study, which demonstrated that intravitreal injection of triamcinolone acetonide improved both visual acuity and ME after 12 months in patients with BRVO 5.…”

Section: Introductionmentioning

confidence: 98%

Functional–morphological parameters, aqueous flare and cytokines in macular oedema with branch retinal vein occlusion after ranibizumab

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…19,20 Many studies have demonstrated elevation of proinflammatory mediators and reduction of antiinflammatory cytokines of the vitreous fluid in RVO patients. 20,25,26 In addition, Yoshimura et al 19 reported the upregulation of cytokine interleukin-6, interleukin-8, and monocyte chemoattractant protein-1, and their contribution to the formation of RVO. Furthermore, many reports disclosed that after antiinflammatory therapy in RVO patients, macular edema, a serious complication of RVO, subsided together with reduced proinflammatory factors in vitreous fluid.…”

Section: Discussionmentioning

confidence: 99%